Hansa Biopharma announces reorganization
Swedish rare disease specialist Hansa Biopharma (STO: HNSA) announced a reorganization of its European and International Commercial and Medical Affairs operations.
This action follows a comprehensive review of the European commercial operations over the past months. The review identified key areas for improvement and investment aimed at addressing recent challenges and enhancing performance and predictability in 2026.
As part of these changes, Hansa has appointed Max Swedish rare disease specialist Hansa Biopharma (STO: HNSA) as vice president, general manager Europe and International, effective immediately. Max will lead both the commercial and medical affairs organizations across the regions and will report to Maria Törnsén, chief operating officer and US President.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze